Published Jun 21, 2023


Google Scholar
Search GoogleScholar

Pia Dey

Debaprasad Parai

Sk Tofajjen Hossain

Samir Kumar Mukherjee



Antimicrobial resistance (AMR) poses a critical challenge to modern medicine. The number of resistance cases worldwide has been increasing exponentially, and it is estimated that by 2050, the AMR mortality rate will be ten times higher than it is today. The emergence of the coronavirus disease 2019 (COVID-19) pandemic compromised the research on AMR by deprioritizing proper monitoring of preventive measures and control programs, innovation and global health programs, and use antimicrobial stewardship (AS). With the current scenario of sporadic COVID-19 cases around the world, it is impossible to accurately evaluate the impact that the pandemic had on AMR and AS due to insufficient reports. However, it’s possible to speculate what the scenario will look like by surveying the escalation in unmethodical antimicrobial, the increase in secondary bacterial and fungal infections, and the extension in hospital stay and adverse medical exigency during the second wave when compared to the first wave. COVID-19 exposed the harsh reality that even countries with the best medical facilities struggled to meet national healthcare needs during a pandemic. In such circumstances, the clinical and scientific communities need to understand that available global medical amenities would
be insufficient to face an upcoming AMR pandemic. Therefore, international surveillance systems need to highlight the deficiencies in AMR containment and mitigation and develop strategies to address future challenges.


antimicrobial resistance; corona virus disease; antimicrobial stewardship; antimicrobial usages; public health

[1] Scott J. The economic, geopolitical and health impacts of COVID-19, World Economic Forum, 2020.
[2] WHO. WHO Coronavirus (COVID-19) Dashboard, World Health Organiztion, 1–5, 2021.
[3] Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out, Nature, 589: 177–178, 2021.
[4] Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M,et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support covid-19 antimicrobial prescribing, Clinical Infectious Diseases, 71(9): 2459–2468, 2020.
doi: C
[5] Mahida N, Gray J. Antimicrobial stewardship: a COVID casualty?, Journal of Hospital Infection, 106(3): 401–403, 2020.
[6] Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?, Eurosurveillance, 25(45): 2001886, 2020.
[7] Afshinnekoo E, Bhattacharya C, Burguete-García A, Castro-Nallar E, Deng Y, Desnues C, et al. COVID-19 drug practices risk antimicrobial resistance evolution, The Lancet Microbe, 2: 135–136, 2021.
[8] Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance : a global multifaceted phenomenon, Pathogens and Global Health, 109: 309–318, 2016.
doi: 10.1179%2F2047773215Y.0000000030
[9] Arshad M, Mahmood SF, Khan M, Hasan R. Covid -19, misinformation, and antimicrobial resistance, BMJ, 371: m4501, 2020.
[10] WHO. Antimicrobial resistance,World Health Organization, 2020.
[11] US Department of Health and Human Services, CDC. Antibiotic resistance threats in the United States, Centers of Disease Control and Prevention, 1–113, 2019.
[12] Pelfrene E, Botgros R, Cavaleri M. Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?, Antimicrobial Resistance & Infection Control, 10: 21, 2021.
[13] WHO. Global strategy for containment of antimicrobial resistance. World HealthOrganization, 105, 2001.
[14] WHO. The evolving threat of antimicrobial resistance: options for action,World Health Organization, 1–119, 2014.
[15] WHO. World antimicrobial awareness week,World Health Organization, 2015.
[16] Regional Committee for Europe. European strategic action plan on antibiotic resistance, 6:12–15, 2011.
[17] NCDC. National policy for containment of antimicrobial resistance, India, 2011.
[18] National action plan on antimicrobial resistance (NAP-AMR), India, 2017.
[19] Dijk KH and Van L. The world medicines situation: rational use of medicines, World Medicine Situation, 2: 24–30, 2011.
[20] Ansari S, Hays JP, Kemp A, et al. The potential impact of the COVID-19 pandemic on global antimicrobial and biocide resistance: an AMR insights global perspective, JAC-Antimicrobial Resistance, 3(2). 2021.
[21] Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases,Virus Research, 285: 198005, 2020. doi:
[22] Rodríguez-Baño J, Rossolini GM, Schultsz C, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance, Transactions of the Royal Society of Tropical Medicine & Hygiene. 2021.
[23] Langford BJ, So M, Raybardhan S, Leung V, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clinical Microbiology and Infection, 26(12): 1622–1629, 2020.
[24] Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study, Clinical Microbiology and Infection, 27(1): 83–88, 2021.
[25] Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with Coronavirus Disease 2019 (COVID-19): A multi-hospital cohort study, Clinical Infectious Diseases, 72(10): 533–541, 2021.
[26] Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, BMJ, 368: 606, 2020.
[27] Subramanya SH, Czyż DM, Acharya KP, et al. The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship, Virus Disease, 23(2): 1–8,2021.
[28] Chedid M, Waked R, Haddad E, et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy, Journal of Infection and Public Health,14(5): 570–576, 2021.
[29] Chang CY, Chan KG. Underestimation of co-infections in COVID-19 due to nondiscriminatory use of antibiotics, Journal of Infection, 81(3): 29–30, 2020.
[30] Martinez KA, Rood M, Jhangiani N, et al. Association between antibiotic prescribing for respiratory tract infections and patient satisfaction in direct-to-consumer telemedicine, JAMA-Internal Medicine, 178(11): 1558–1560, 2018.
[31] Ray KN, Shi Z, Gidengil CA, et al. Antibiotic prescribing during pediatric direct-to-consumer telemedicine visits, Pediatrics, 143(5): e20182491, 2019.
[32] Clancy C, Nguyen M. COVID-19, superinfections and antimicrobial development: What can we expect?, Clinical Infectious Diseases, 71(10): 2736–2743, 2020.
doi: Fcid%2Fciaa524
[33] NIH, COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2 infection, 2021.
[34] Sell TK, Hosangadi D, Trotochaud M. Misinformation and the US Ebola communication crisis: analyzing the veracity and content of social media messages related to a fear-inducing infectious disease outbreak, BMC Public Health, 20(1):550, 2020.
[35] Islam MS, Sarkar T, Khan SH, et al. COVID-19-Related infodemic and its impact on public health: a global social media analysis, American Journal of Tropical Medicine and Hygeine, 103: 1621–1629, 2020.
[36] Glasziou PP, Sanders S, Hoffmann T. Waste in covid-19 research, BMJ, 369: 1847, 2020.
[37] Wang Y, Hao H, Platt LS. Examining risk and crisis communications of government agencies and stakeholders during early-stages of COVID-19 on Twitter, Computers in Human Behaviours, 114: 106568, 2021.
[38] Gonsalves G, Yamey G. Political interference in public health science during Covid-19, BMJ, 371:19–20, 2020.
[39] Azad A. Antimicrobial crisis, DAWN.COM., 2020.
[40] Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge, Infection Control & Hospital Epidemiology, 42(1): 84–88, 2021.
[41] Shehadeh M, Suaifan G, Darwish RM, et al. Knowledge, attitudes and behavior regarding antibiotics use and misuse among adults in the community of Jordan. A pilot study, Saudi Pharmaceutical Journal, 20(2): 125–133, 2012.
[42] Wang Z, Wang J, He J. Active and effective measures for the care of patients with cancer during the COVID-19 spread in China, JAMA Oncology, 6(5): 631–632, 2020.
doi: 10.1001/jamaoncol.2020.1198OECD
[43] Stemming the superbug tide: just a few dollars more, OECD Health Policy Studies, OECD Publication Paris, 2018.
[44] Mazdeyasna H, Nori P, Patel P, et al. Antimicrobial stewardship at the core of COVID-19 response efforts: implications for sustaining and building programs, Current Infectious Disease Reports, 22(9): 23, 2020.
[45] Usman M, Farooq M, Hanna K. Environmental side effects of the injudicious use of antimicrobials in the era of COVID-19, Science of the Total Environment, 745: 141053, 2020.
[46] Wilson LA, Rogers Van Katwyk S, Fafard P, et al. Lessons learned from COVID-19 for the post-antibiotic future, Global Health, 16: 94, 2020.
[47] Canto NR, GijoÂn D, Ruiz-Garbajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic, Current Opinion in Critical Care, 26(5): 433–441, 2020.
[48] Waiting Times for Health Services: Next in Line, OECD Health Policy Studies,OECD Publication Paris, 2020.
[49] CCA. When antibiotics aail: the expert panel on the potential socio-economic impacts of antimicrobial resistance in Canada, Council of Canadian Academies, 2019.
[50] Liberati A, D’Amico R, Pifferi S, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care, Cochrane Database System Reviews, 4: CD000022, 2009.
[51] MacIntyre CR, Chughtai AA, Barnes M, Ridda I, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09, BMC Infectious Diseases, 18(1): 637, 2018.
[52] Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics, Frontiers in Microbiology, 8: 1041, 2017.
[53] Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, 76(1): 30–42, 2021.
[54] The recovery trial, 2022.
[55] WHO. “Solidarity” clinical trial for COVID-19 treatments, World Health Organization, 2021.
[56] Maugueret TMJ, Walker SL. Rapid detection of Obesumbacterium proteus from yeast and wort using polymerase chain reaction, Letters in Applied Microbiology, 35(4): 281–284, 2002.
[57] Molento MB. COVID-19 and the rush for self-medication and self-dosing with ivermectin: a word of caution, One Health, 10:100148, 2020.
[58] Torres NF, Chibi B, Middleton LE, et al. Evidence of factors influencing self-medication with antibiotics in low and middle-income countries: a systematic scoping review, Public Health, 168: 92–101, 2019.
[59] Rezasoltani S, Yadegar A, Hatami B, et al. Antimicrobial resistance as a hidden menace
lurking behind the COVID-19 outbreak: the global impacts of too much hygiene on AMR,
Frontiers in Microbiology, 11: 590683, 2020.
[60] Stoker ML, Newport E, Hulit JC, et al. Impact of pharmacological agents on mitochondrial function: a growing opportunity?, Biochemical Society Transactions, 47(6): 1757–1772, 2019.
[61] Economic Times. Third wave of COVID-19 definitely underway in Britain, says vaccine expert, 2021.
[62] WHO. Clinical Management of COVID-19, World Health Organization, 2020.
[63] Getahun H, Smith I, Trivedi K, et al. Tackling antimicrobial resistance in the COVID-19 pandemic, Bulletin of the World Health Organization, 98(7): 442–442A, 2020.
How to Cite
Dey, P., Parai, D., Hossain, S. T., & Mukherjee, S. K. (2023). The aftermath of corona virus disease on antimicrobial resistance across low- and middle-income countries. Universitas Scientiarum, 28(2), 183–199.